A Pilot Pre-Surgical Study Evaluating Anti-Pd-L1 Durvalumab (Durva) Plus Anti-Ctla-4 Tremelimumab (Treme) In Patients With Muscle-Invasive, High-Risk Urothelial Bladder Carcinoma Who Are Ineligible For Cisplatin-Based Neoadjuvant Chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要